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DOI 10.1016/j.ccr.2011.11.002SUMMARYBreast cancer patients often develop locoregional or distant recurrence years after mastectomy. Under-
standing the mechanism of metastatic recurrence after dormancy is crucial for improving the cure rate for
breast cancer. Here, we characterize a bone metastasis dormancy model to show that aberrant expression
of vascular cell adhesion molecule 1 (VCAM-1), in part dependent on the activity of the NF-kB pathway,
promotes the transition from indolent micrometastasis to overt metastasis. By interacting with the cognate
receptor integrin a4b1, VCAM-1 recruits monocytic osteoclast progenitors and elevates local osteoclast
activity. Antibodies against VCAM-1 and integrin a4 effectively inhibit bone metastasis progression and
preserve bone structure. These findings establish VCAM-1 as a promising target for the prevention and
inhibition of metastatic recurrence in bone.INTRODUCTION
One mysterious feature of metastases is that distant relapse can
occur many years after successful primary tumor removal and
clinically disease-free survival (Aguirre-Ghiso, 2007). The latency
before distant metastasis relapse is defined as metastasis
dormancy. Understanding the mechanism of dormancy and its
reactivation has important clinical implications for controlling
metastatic progression and maintaining patients in a disease-
free state (Chambers et al., 2002; Goss and Chambers, 2010).
In preclinical models, cancer can remain dormant either as
quiescent cells (cellular dormancy) or as indolent small clustersSignificance
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dormancy) (Aguirre-Ghiso, 2007). Various possible mechanisms
of dormancy have been suggested based on studies performed
in preclinical models, including inefficient angiogenesis, anti-
body- or T cell-mediated immune surveillance, lack of prolifera-
tive signals, and the activity of metastasis suppressor genes and
microRNAs, although the extent to which these mechanisms
reflect clinical dormancy is unclear (Aguirre-Ghiso, 2007; Goss
and Chambers, 2010). Clinical dormancy in patients has been
extensively studied in breast cancer. Time distribution analyses
of both mortality and recurrence showed an early polynomial-
like curve and a late persistent rate for up to more than 20 yearsetastasis represents a crucial turning point in breast cancer.
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VCAM-1 Activates Indolent Bone Metastasis(Demicheli et al., 1996). Interrupted and prolonged dormancy
was proposed to explain the bimodal pattern (Demicheli,
2001), yet with little molecular insight.
Postoperative distant recurrence arises invariably from
disseminated tumor cells, which are often found in the bone
marrow of breast cancer patients without any clinical sign of
metastasis (Braun et al., 2005; Klein, 2009). Bone metastasis
is a frequent complication of breast cancer and is often accom-
panied by debilitating bone fracture, severe pain, nerve
compression, and hypercalcemia (Weilbaecher et al., 2011).
Bone metastasis is characterized by the intricate interaction
between tumor cells and bone microenvironment. In breast
cancer, continuous expansion of osteolytic bone metastasis is
driven by the ‘‘vicious cycle’’ of tumor-dependent activation of
bone-degrading osteoclasts and bone stroma-dependent stim-
ulation of tumor malignancy (Weilbaecher et al., 2011). There-
fore, identification of tumor-derived osteoclastogenic factors
may provide new potential therapeutic targets. Currently, it is
unknown whether molecules involved in the vicious cycle are
also important for driving the transition from indolent micrometa-
stasis to overt metastasis in bone. This lack of understanding
can be largely explained by the paucity of appropriate animal
models that mimic the metastatic relapse process. Here, we
report the establishment of a dormancy-reactivation model of
breast cancer bone metastasis. Using this model, we linked
osteoclast activation with the switch from micrometastasis to
osteolytic macrometastasis, and identified vascular cell adhe-
sion molecule-1 (VCAM-1) as a key regulator of this process.
VCAM-1 is a member of the transmembrane immunoglobulin
superfamily (Osborn et al., 1989). Proteolytic shedding of
VCAM-1 also generates a soluble form of VCAM-1 (Garton
et al., 2003). The predominant receptor for VCAM-1 is integrin
a4b1 (i.e., very late antigen-4, VLA-4), which is expressed by
many cell types of the hematopoietic lineage, including B and T
lymphocytes, monocytes, eosinophils, and basophils (Carter
and Wicks, 2001). VCAM-1 is expressed by cytokine-activated
endothelial cells (Osborn et al., 1989) and VCAM-1-a4b1 binding
plays an important role in mediating leukocyte adhesion and
transendothelial migration during inflammation (Springer, 1994),
which may be the underlying mechanism for VCAM-1 function
in rheumatoid arthritis (Carter andWicks, 2001) and early athero-
sclerosis (Cybulsky et al., 2001). Aberrant expression of VCAM-1
in cancer cells was documented in preclinical models as well as
patient samples of gastric cancer (Ding et al., 2003), renal cell
carcinoma (Lin et al., 2007), and breast cancer (Chen et al.,
2011). However, it is unknown whether tumor-derived VCAM-1
has any functional role in breast cancer metastasis to bone.
Combining the power of functional genomics and a multiphoton
imaging technique, ex vivo imaging of bonemetastasis (EviBoM),
we discovered a role of VCAM-1 in promoting the outgrowth of
indolent bone micrometastasis and established VCAM-1 as
a promising target for preventing metastatic recurrence in bone.
RESULTS
Identification of VCAM-1 as a Crucial Activator
of Indolent Bone Micrometastasis
We previously used an in vivo selection strategy to derive bone-
metastatic variants of the MDA-MB-231 breast cancer cell line702 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Incin order to identify bone metastasis genes (Kang et al., 2003).
Dilution cloning of the parental MDA-MB-231 population
revealed a small percentage of pre-existing highly bone-
metastatic cells that overexpress the bone-metastasis gene
signature, including genes such as CXCR4, IL11, CTGF,
MMP1, and OPN (Kang et al., 2003). Consistent with the func-
tional importance of these genes, single cell-derived popula-
tions (SCPs) of MDA-MB-231 that lack the expression of the
bone metastasis gene signature (e.g., SCP3, SCP4, SCP6,
SCP21) were incapable of generating any X-ray-detectable
bone metastases within 100 days after injection (Figures 1A
and 1B; see also Figure 5B in Kang et al., 2003). However, after
more than 4 months, a small percentage (10%) of mice in-
jected with SCP6 developed overt bone metastasis. Cell lines
derived from such a bone lesion (e.g., postdormancy generation
1 [PD1]) possess drastically increased metastatic potential
(Figures 1A–1C). Close monitoring of mice injected with lucif-
erase-labeled SCP6 by the more sensitive bioluminescence
imaging (BLI) revealed repeated failure of micrometastases in
bone to expand to become overt macrometastases (Figure S1A
available online, highlighted by yellow circles), in contrast to
the rapid development of osteolytic lesions by highly bone-
metastatic lines such as SCP25 (Figure S1A). This long ‘‘lead
time’’ before the infrequent overt bone metastasis formation
(Figure S1A, red circle) from indolent micrometastasis is similar
to the clinical observation of metastatic dormancy and subse-
quent relapse. From the bone metastases formed by PD1,
second-generation sublines (PD2) were isolated (Figure 1A).
Most of the PD2 sublines (PD2A, PD2B, PD2C, PD2D, and
PD2E) metastasize to bone as efficiently as PD1, whereas one
subline, PD2R, significantly lost its metastatic potential and
was therefore considered as a partial revertant to the dormant
state (Figures 1B and 1C). These near-isogenic sublines that
were derived from a common progenitor but had dramatic
differences in metastatic abilities represented an ideal cohort
to identify crucial drivers of outgrowth from indolent bone
micrometastasis.
To ensure the lineage relationships between different sublines
derived in this study and the parental MDA-MB-231, we ana-
lyzed genomic copy number changes using array comparative
genomic hybridization (CGH) (Figure S1B). PD1 and SCP6
shared very similar chromosomal profiles to MDA-MB-231, sug-
gesting that the dramatic differences in their metastatic abilities
are not likely the result of gross genomic alterations or accidental
contaminations from other cell lines.
Because the highly aggressive bone-metastatic ability of
the PD sublines is similar to that of the MDA-MB-231 variants
previously isolated from in vivo selection (Kang et al., 2003),
we first tested whether the PD sublines activated the same
bone metastasis signature (Kang et al., 2003). Surprisingly,
none of the previously described bone metastasis genes was
found to be upregulated in the PD sublines (Figures S1C and
S1D), suggesting that an independent mechanism was devel-
oped by the PD cells to acquire the bone-metastatic ability.
Microarray profiling revealed differentially expressed genes
between the highly metastatic PD1/PD2 lines and the weakly
metastatic lines (SCP3, SCP4, SCP6, MDA-MB-231, and
PD2R) (Figures 1D and 1E; Table S1). Several genes overex-
pressed in PD1/PD2 lines have been implicated in breast cancer,.
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Figure 1. Identification of VCAM-1 as a Bone Metastasis Gene in a Mouse Model of Metastatic Dormancy and Activation
(A) Relationship of parental SCP6 and postdormancy (PD) sublines. Sublines with strong bone-metastatic ability are color-coded in red and sublines with weak
bone-metastatic ability are color-coded in green.
(B and C) Kaplan-Meier curve of bone metastasis development of different cell lines with BLI of representative mice (n = 10).
(D) Supervised clustering of samples using genes differentially expressed between weak (green) and strong (red) bone-metastatic cell lines. Genes highlighted in
red were functionally tested.
(E) Differential expression of VCAM-1 in parental and PD sublines as detected by western blot analysis.
(F) VCAM-1 KD in PD2D as detected by western blot analysis.
(G) Kaplan-Meier curve of bone metastasis development of the indicated PD2D cells (n = 8). **p < 0.01, #p > 0.1 by log-rank test.
(H) Representative BLI of mice from (G) on day 63 and day 112.
(I) Representative X-rays with arrows pointing to osteolytic lesions. See also Figure S1 and Table S1.
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VCAM-1 Activates Indolent Bone Metastasisincluding IL1B (Jin et al., 1997), TFPI2 (Wojtukiewicz et al., 2003),
MAGEB2 (Lurquin et al., 1997), KLRC1 (Minn et al., 2005), and
VCAM-1 (Minn et al., 2005). However, none of them has been
previously linked to bone metastasis.
To determine whether one or more of these five genes con-
tributed to metastasis, we used short hairpin RNAs (shRNAs)
to stably silence each gene in a representative strongly meta-
static PD line, PD2D. Knockdown (KD) of IL1B, TFPI2,MAGEB2
or KLRC1 had no effect on bone metastasis (Figure S1E). Three
different VCAM-1 shRNAs showed different KD efficiency (Fig-
ure 1F). Whereas KD1 and KD2 significantly reduced VCAM-1
expression, KD3 did not reduce VCAM-1 level (Figure 1F) and
thus served as an additional negative control. The two efficient
knockdowns significantly abolished the bone-metastatic ability
(Figures 1G and 1H). X-rays (Figure 1I) revealed the osteolytic
nature of the bone lesions formed by control cells and the atten-Canuation of this phenotype in the KD cells. To further confirm the
specificity of VCAM-1 KD, VCAM-1 expression was rescued
in the KD1 subline by stably expressing an shRNA-resistant
VCAM-1 coding sequence (Figure 2A). When inoculated in vivo,
the rescue cells showed recovered metastatic potential (Figures
2B and 2C). Collectively, these results suggest that VCAM-1 is
essential for the acquired osteolytic bone-metastatic ability in
the PD lines.
Acquisition of VCAM-1 Expression by In Vivo Evolution
Escape from metastasis dormancy was hypothesized to occur
through adaptive changes of micrometastases (Weinberg,
2008), although this argument has not been supported by
evidence collected from a mouse model with a natural history
of metastatic progression from dormancy. Most previous
metastasis models enriched subpopulations with inherentlycer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc. 703
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Figure 2. Essential Role of VCAM-1 in Bone Metastasis
(A) Rescued VCAM-1 expression in the VCAM-1-KD PD2D subline as detected by western blot analysis.
(B) Kaplan-Meier representation of bone metastasis relapse by control and VCAM-1-rescued cell lines in (A) (n = 6). **p < 0.01 (log-rank test).
(C) Hematoxylin and eosin staining of tibia showing presence or absence of overt metastatic tumors (T) in bone (B) by different tumor cells. Scale bar,
200 mm.
(D) Ectopic overexpression of VCAM-1 in SCP6 as detected by western blot analysis.
(E) BLI curves of in vivo bone metastasis assay with SCP6 variants. Data represent the mean ± SD (n = 6). No time point showed statistical significance
(Mann-Whitney test).
(F) Ectopic overexpression of VCAM-1 in PD2R as detected by western blot analysis.
(G) BLI curves of bone metastasis development by control and VCAM-1-overexpressing PD2R cells. Data represent the mean ± SEM (n = 10). ***p < 0.001
(Mann-Whitney test).
(H) Representative BLI of mice in (G).
(I) Endogenous expression of VCAM-1 in the murine cell line TM40D and the subline TM40D-MB, and VCAM-1 KD in TM40-MB, as detected by western
blot analysis.
(J) BLI curves of bone metastasis development by the indicated TM40D-MB cells. Data represent the mean ± SEM (n = 10). *p < 0.05, **p < 0.01 (Mann-
Whitney test).
(K) Representative BLI of mice in (J) on day 21 and day 42. See also Figure S2.
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VCAM-1 Activates Indolent Bone Metastasisstronger metastatic potential in a cell line through in vivo selec-
tion (Kang et al., 2003; Minn et al., 2005). Without the in vivo
evolution of dormancy, this approach is unlikely to find genes
critical for activation of overt bone metastasis from dormant
micrometastases. To evaluate our model in this respect, we
investigated whether VCAM-1 upregulation was a newly evolved
event during the outgrowth from micrometastasis of SCP6.
Highly abundant VCAM-1 protein was detected in aggressive
PD lines with localization restricted to cell membrane (Figures
S2A and S2B), allowing flow cytometric analysis of VCAM-1+704 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inccells. VCAM-1 expression pattern was examined exhaustively
in SCP6 using fluorescence-activated cell sorting (FACS) anal-
ysis of 8.7 3 106 cells (Figure S2C). Only 17 cells were stained
positive. This extremely low percentage of VCAM-1+ cells was
determined to be a false positive when the sorted VCAM-1+ cells
were expanded into a larger population and VCAM-1 expression
was re-examined (Figure S2C). Therefore, we conclude that
VCAM-1 upregulation most likely evolved in vivo during the
natural metastasis progression from indolent micrometastasis
to overt macrometastasis..
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Figure 3. Prometastatic Activity of VCAM-1 in Additional Bone Metastasis Models
(A) Ectopic overexpression of VCAM-1 in MCF7 as detected by western blot analysis.
(B) Kaplan-Meier curve of bone metastasis development of control and overexpression MCF7 cells (n = 10). **p < 0.01 (log-rank test).
(C) Representative BLI (day 125) and X-rays (day 154) of mice from (B). Arrows point to osteolytic lesions.
(D) Ectopic overexpression of VCAM-1 in CN34 as detected by western blot analysis.
(E) Kaplan-Meier curve of bone metastasis development of control and VCAM-1 overexpressing CN34 cells (n = 10). *p < 0.05 (log-rank test).
(F) Representative BLI (day 125) and X-rays (day 154) of mice from (E). Arrows point to osteolytic lesions.
(G) Ectopic overexpression of VCAM-1 in MDA-MB-435 as detected by western blot analysis.
(H) Kaplan-Meier curve of bone metastasis development of control and VCAM-1-overexpressing MDA-MB-435 cells (n = 10). *p < 0.05 (log-rank test).
(I) Representative BLI (day 42) of mice from (H).
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VCAM-1 Activates Indolent Bone MetastasisValidation of the Prometastatic Role of VCAM-1 in Other
Bone Metastasis Models
To further evaluate whether VCAM-1 is sufficient for bonemetas-
tasis, we overexpressed it in SCP6 and the revertant line PD2R.
While ectopic expression of VCAM-1 was insufficient to confer
bone-metastatic ability to SCP6 (Figures 2D and 2E), it was suffi-
cient to promote the outgrowth of bone metastases formed by
PD2R, which otherwise failed to further expand 50 days after
injection (Figures 2F–2H). This result indicates the initial conver-
sion from micrometastases to overt macrometastases required
more than VCAM-1 upregulation in the genetic background of
SCP6. Nevertheless, VCAM-1 overexpression alone is sufficient
to rescue themetastatic property of PD2R, which is more closely
related to PD1.
To test whether VCAM-1 function in promoting bone metas-
tasis was restricted to MDA-MB-231, we used other bone
metastasis models. Recently, the TM40D murine mammaryCantumor cell line was subjected to in vivo selection to establish
the highly bone-metastatic TM40D-MB subline. Interestingly,
VCAM-1 was one of the 14 genes found to be significantly over-
expressed in TM40D-MB (Li et al., 2008) (Figure 2I). We silenced
VCAM-1 expression in TM40D-BM and observed dramatic
reduction of bone metastasis (Figures 2I–2K).
We further tested the prometastatic function of VCAM-1 in
several human breast cancer cell lines withmild bone-metastatic
abilities. MCF7 is an estrogen receptor (ER)-positive cell line
that generates slowly growing bone metastases in less than
20% of inoculated mice (Lu et al., 2009). Ectopic expression of
VCAM-1 in MCF7 led to formation of osteolytic bone metastases
in 69% of mice (Figures 3A–3C). Two ER-negative cancer cell
lines were tested in addition to the MDA-MB-231 derivatives
(also an ER-negative model). CN34 was recently isolated from
pleural effusion and showed marginal potential to form bone
metastasis (Zhang et al., 2009). VCAM-1 overexpressioncer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc. 705
IgG control Anti-VCAM-1
D35
D69
CBA
*
0.1
1
10
102
103
104
105
0 10 20 30 40 50 60
Days after injection
B
o
n
e
 
m
e
t
 
B
L
I
 
s
i
g
n
a
l
s IgG control
Anti-VCAM-1
D
B
o
n
e
 
m
e
t
 
B
L
I
 
s
i
g
n
a
l
s
 
(
x
1
0
3
)
0
1
2
3
4
5
62 72 82 92
Days after injection
IgG control
Anti-VCAM-1
*
E
0 20 40 60 80
Days after injection
IgG control
anti- 4
0.1
1
10
102
103
104
105
B
o
n
e
 
m
e
t
 
B
L
I
 
s
i
g
n
a
l
s
**
D36
D65
FIgG Anti- 4
IgG control Anti-VCAM-1 Anti- 4
70
Cell line: PD2D
Cell line: PD2D
Figure 4. Antibody Therapy Targeting VCAM-1 and Integrin a4 Inhibits Bone Metastasis
(A) BLI curves of bone metastasis development by PD2D cells in nude mice with control IgG or anti-VCAM-1 (clone P3C4) treatment started from day 10. Data
represent the mean ± SEM (n = 6). *p < 0.05 (Mann-Whitney test).
(B) Representative BLI of mice treated with IgG or anti-VCAM-1 antibodies.
(C) BLI curves of bone metastasis progression by PD2D cells with control IgG or anti-VCAM-1 treatment started from day 62. BLI signals were normalized to day
62 to facilitate comparison. Data represent the mean ± SEM (n = 6). *p < 0.05 (Mann-Whitney test).
(D) BLI curves of bonemetastasis development by PD2D cells with control IgG or anti-a4 (clone PS/2) treatment started from day 0 until day 21. Data represent the
mean ± SEM (n = 10). **p < 0.01 (Mann-Whitney test).
(E) Representative BLI of mice treated with IgG or anti-a4.
(F) X-ray of PD2D-injected mice treated with anti-VCAM-1 (A) or anti-a4 (D) at the end of experiments. Arrows point to osteolytic lesions. See also Figure S3.
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VCAM-1 Activates Indolent Bone Metastasissubstantially increased the osteolytic bone metastasis of CN34
cells (Figures 3D–3F). Finally, MDA-MB-435, coexpressing both
epithelial and melanocytic markers (Chambers, 2009), contains
discernable level of VCAM-1 (Figure 3G) and displays mild
aggressiveness tobone (Lu et al., 2009). VCAM-1overexpression
further enhanced bone colonization efficiency of MDA-MB-435
(Figures 3H and 3I). It should be noted that the prometastasic
effect of VCAM-1 overexpression in CN34 was less dramatic
compared with MCF7 and MDA-MB-435, probably reflecting
the requirement for other genes in CN34 to colonize the bone
more efficiently. Taken together, we conclude that VCAM-1 has
a general prometastatic function in bone metastasis.
Therapeutic Targeting of VCAM-1 or Cognate Receptor
by Antibodies
To evaluate the therapeutic benefit of targeting VCAM-1 using
a more clinically applicable approach, we used a previously
developed monoclonal antibody (clone P3C4) capable of block-
ing VCAM-1 binding activity (Dittel et al., 1993). To test the anti-
metastatic activity of the antibody, mice were treated 10 days
after the intracardiac injection of PD2D cells to mimic adjuvant706 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inctherapy.Mice treated with control immunoglobulin G (IgG) devel-
oped aggressive bone metastases that grew continuously,
whereas those treated with anti-VCAM-1 only developed a low
level of bone metastasis burden that reached a plateau within
50 days (Figures 4A and 4B). Dramatically diminishedmetastasis
was also achieved when antibody was applied following an
early adjuvant protocol (Figures S3A–S3C). To evaluate whether
VCAM-1 antibody can inhibit established metastases, mice
were treated with antibody 62 days after cell injection, and
again demonstrated efficacy in impeding metastasis growth
(Figure 4C).
VCAM-1 is a ligand for integrin a4b1 and only binds weakly
to integrin a4b7 (Springer, 1994). Because neither SCP6 nor
PD cells express a4 (Figure S3D), in vivo VCAM-1-integrin
interaction, if existent, is expected to occur between tumor
and murine host cells. Because a4 is the common integrin
subunit, we used a previously developed neutralizing mono-
clonal antibody against murine a4, clone PS/2 (Miyake et al.,
1991). As expected, mice injected with PD2D and treated with
anti-a4 showed less bone metastasis formation and better
preserved bone structure (Figures 4D and 4E)..
IgG control Anti-VCAM-1 Anti- 4
T
B
T T
B
B
T
R
A
P
H
&
E
T
SCP6 PD1
PD2D PD2D-KD1
***
***
#
0
4
8
12
16
S
C
P
6
P
D
1
P
D
2
D
P
D
2
D
-
K
D
1M
u
l
t
i
n
u
c
l
e
a
t
e
d
 
T
R
A
P
+
o
s
t
e
o
c
l
a
s
t
/
m
m
2
B
o
n
e
 
m
a
r
r
o
w
M
C
3
T
3
-
E
1
7
F
2
R
A
W
 
(
p
r
e
-
O
c
)
R
A
W
 
(
m
a
t
u
r
e
 
O
c
)
Gapdh
4
1
4
1
4
1
RAW264.7 (pre-Oc)
D5
D1
D2
No coating BSA VCAM-1
Anpep
Cacr
Ptpre
Atp6i
Clcn7
Ctsk
Mmp9
Trap
Mmp14
Ccr1
Itgb3
Itgav
Nfatc1
Mst1r
Car2
Cd14
Stat1
RANKL- + +
VCAM-1- - +
- + +
- - +
- + +
- - +
Day 2 Day 4 Day 5
Src
Cpe
Gsn
Myc
Tlr6
U
p
D
o
w
n
-2.0
-1.0
-0.5
0.0
2.0
5.0
10.0
E
x
p
r
e
s
s
i
o
n
 
(
l
o
g
2
 
t
r
a
n
s
f
o
r
m
e
d
)
A
B
C D
F
E
Figure 5. VCAM-1 Promotes Osteoclast Activation by Direct Interaction with Preosteoclasts
(A) Hematoxylin and eosin (H&E) and TRAP staining of hindlimb long bones showing tumor (T, demarcated by dotted line), bone (B), and TRAP+ (red) osteoclasts.
Mice were injected with PD2D, and samples were obtained from Figure 4F. Scale bar, 100 mm.
(B) In vitro osteoclastogenesis of murine bone marrow cocultured with different tumor cell monolayers. Mature osteoclasts were quantified as multinucleated
TRAP+ (red) cells. Data represent the mean ± SD. ***p < 0.001, #p > 0.5 (Student’s t test and Mann-Whitney test). Scale bar, 250 mm.
(C) RT-PCR showing a4b1 expression in RAW264.7 before as well as after induced differentiation, but not in osteoblast cell lines (MC3T3-E1 and 7F2). Murine
bone marrow was used as a positive control.
(D) Surface expression of a4b1 by RAW264.7 revealed by FACS staining. Scale bar, 25 mm.
(E) RANKL-induced RAW264.7 differentiation on precoated plates. Arrows indicate early formation of multinucleated cells. TRAP staining on day 5 showed
morphologically larger osteoclasts in VCAM-1-coated plate. Scale bar, 100 mm.
(F) Expression pattern of known osteoclast differentiation markers in RAW264.7 cultured with or without VCAM-1-coating in the presence or absence of RANKL
induction. The markers, quantified by quantitative RT-PCR, include known upregulated (Up) and downregulated (Down) genes during osteoclast differentiation.
See also Figure S4.
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VCAM-1 Activates Indolent Bone MetastasisVCAM-1 Promoting Osteoclast Activation in Bone
Metastasis
Because highly bone-metastatic PD cells do not possess
a significantly higher proliferation rate than the dormant SCP6
and weakly metastatic PD2R cells in vitro (Figure S4A), we
investigated the potential mechanism for VCAM-1 in conferring
the growth advantage of PD cells in the bone microenviron-
ment. The vicious cycle in bone metastasis, mediated by the
activation of bone-degrading osteoclasts, has been well known
to play a central role in determining the osteolytic nature and
aggressiveness of breast cancer bone metastasis (WeilbaecherCanet al., 2011). We hypothesized that VCAM-1 promotes bone
metastasis through activating osteoclasts, thereby instigating
the establishment of the vicious cycle. First, we examined oste-
oclast activity in IgG or antibody-treated bone metastases
(adjuvant therapy protocol) by staining the osteoclast marker
tartrate-resistant acid phosphatase (TRAP). TRAP+ osteoclasts
were abundantly enriched in the bone metastases formed by
PD2D in the IgG-treated mice (Figure 5A). Other parts of the
bone did not have elevated number of TRAP+ osteoclasts, sug-
gesting a local osteoclast-inducing milieu by PD2D cells (Fig-
ure S4B). Dramatically weaker osteoclast activity was observedcer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc. 707
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VCAM-1 Activates Indolent Bone Metastasisin metastases treated with anti-VCAM-1 or anti-a4 (Figure 5A;
Figure S5B). Metastases formed by PD2R with ectopic
VCAM-1 overexpression also contained numerous TRAP+ oste-
oclasts (Figure S4C).
To directly test whether VCAM-1 expressed on tumor cells
could influence osteoclast differentiation, we cocultured SCP6
or VCAM-1+ PD cells with primary murine bone marrow cells
under conditions inductive of osteoclast differentiation. Signifi-
cantly, more TRAP+ multinucleated osteoclasts formed when
cocultured with PD1 or PD2D compared to SCP6 (Figure 5B).
VCAM-1 KD diminished the ability of PD2D to enhance osteo-
clastogenesis (Figure 5B). Bone marrow contains a heteroge-
neous population of cells. VCAM-1 may interact directly with
osteoclast progenitors to influence their differentiation, or may
instead act through an intermediate cell type, such as osteo-
blasts (Weilbaecher et al., 2011). To distinguish these two possi-
bilities, we analyzed the expression pattern of a4b1 in twomurine
osteoblast cell lines (MC3T3-E1 clone 4 and 7F2) and onemurine
preosteoclast cell line (RAW264.7) using RT-PCR (Figure 5C)
and flow cytometry (Figure 5D). Although b1 was ubiquitously
expressed, a4 was only expressed by RAW264.7 (before and
after differentiation). Therefore, tumor cells and preosteoclasts,
given physical proximity, could interact directly via VCAM-1-
a4b1 binding. This result allowed us to simplify the analysis of
VCAM-1 function in osteoclastogenesis by precoating culture
plates with recombinant VCAM-1 before seeding RAW264.7.
VCAM-1 coating led to earlier multinucleation and eventually
larger cell size with more nuclei in mature TRAP+ osteoclasts
(Figure 5E).
One obvious explanation for the enhanced multinucleation
would be that VCAM-1 induced differentiation. However, when
we examined the expression of 19 upregulated and 3 downregu-
lated genes known to be tightly and functionally correlated with
osteoclast differentiation (Yang et al., 2008), VCAM-1 coating
and BSA coating showed similar patterns during osteoclast
differentiation (Figure 5F). In addition, VCAM-1 coating did not
change the level of phosphorylated Src, extracellular-regulated
kinase, or Akt in RAW264.7 (Figure S4D). Therefore, the
enhanced osteoclast multinucleation may simply be the result
of more attachment of preosteoclasts to a VCAM-1-coated
surface and more cell fusion favored by closer cell juxtaposition.
Translating this hypothesis in vivo, soluble VCAM-1 (sVCAM-1)
and membrane-bound VCAM-1 on tumor cells may recruit and
arrest more osteoclast progenitors to provide an osteoclastic
niche.
VCAM-1-Mediated Attraction of Osteoclast Progenitors
sVCAM-1 produced by PD cells was readily detectable in condi-
tioned medium as well as in serum from tumor-bearing mice
(Figure S4E), suggesting a potential role of VCAM-1 in recruiting
circulating osteoclast precursors to promote osteoclastogene-
sis. We tested this hypothesis by first showing that recombinant
VCAM-1 is a chemoattractant for preosteoclasts by a standard
checkerboard analysis (Figure S5A). VCAM-1-a4b1 binding
was essential for chemoattraction (Figure 6A), and sVCAM-1
secreted by tumor cells was able to attract preosteoclasts
(Figure 6B). Second, we demonstrated a significantly higher
adhesion rate of RAW264.7 cells to VCAM-1+ PD2D cells than
SCP6 or PD2D-KD1 (Figures S5B and S5C). Scanning electron708 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Incmicroscopy revealed tight attachment of RAW264.7 cells to
PD2D and loose juxtaposition to SCP6 or PD2D-KD1 (Figure 6C).
Next, we attempted to analyze in vivometastases for evidence of
osteoclast progenitor attraction. A prerequisite for host cells to
interact with VCAM-1+ tumor cells is a4b1 expression. Murine
bone marrow analysis revealed a4+b1+ and a4-b1+ subpopula-
tions in the CD11b+ monocytes (Figure 6D). CD11b+ monocytes
are known to contain osteoclast progenitors (Ishii et al., 2009).
Intriguingly, the a4+b1+ subpopulation differentiated into signifi-
cantly more multinucleated TRAP+ osteoclasts upon macro-
phage-colony stimulating factor (M-CSF) and receptor activator
for NF-kB ligand (RANKL) treatment (Figure 6D). Therefore,
VCAM-1+ PD cells may attract the a4+b1+ osteoclast progenitors
in vivo to promote bone metastasis. Indeed, we observed the
enrichment of osteoclast progenitors, in particular the a4+b1+
subpopulation, in bonemetastases formed by VCAM-1+ PD cells
(Figures 6E and 6F). Conversely, mice with PD2D bone metas-
tases contained a lower percentage of CD11b+ cells in the
peripheral blood (Figure 6G).
If bone metastases attract and immobilize osteoclast pro-
genitors through VCAM-1 activity, transient blocking of
VCAM-1 by neutralizing antibodies should release the attached
cells from the tumor. However, this hypothesis is difficult to test
with the current methodologies because FACS analysis of
bone marrow and blood composition may be complicated by
VCAM-1-dependent physiological homing of hematopoietic
cells (Papayannopoulou et al., 2001). Furthermore, it is difficult
to provide information on dynamic cell movement using stan-
dard histology. To overcome these technical challenges, we
developed the real-time imaging technique EviBoM by incorpo-
rating BLI with multicolor multiphoton laser-scanning micros-
copy. To simultaneously detect tumor cells and stromal cells,
we stably expressed mKeima (Kogure et al., 2006) to label
tumor cells and generated nude mice with enhanced green
fluorescent protein (EGFP)-labeled monocytes by crossing
CX3CR1-EGFP knock-in mice (Jung et al., 2000) with nude
mice. mKeima showed strong red fluorescence intensity and
superior spectral overlap with EGFP at wavelengths from 900
to 1000 nm, allowing simultaneous detection of mKeima+ tumor
cells and EGFP+ monocytes (Figure S5D). After the formation of
osteolytic bone metastasis detected by whole mouse BLI, we
dissected the long bone, identified the location of metastasis
by ex vivo BLI, and embedded the BLI-positive bone section
in agarose. We adapted a previously described method for
imaging GFP+ hematopoietic stem cells ex vivo in the mouse
long bone (Xie et al., 2009) and analyzed the dynamics of
tumor-monocyte interaction in bone metastasis (Figure 6H).
Using EviBoM, we found that movement velocity of CX3CR1-
EGFP+ monocytes in the area of PD2D bone metastases was
significantly increased after anti-VCAM-1 antibody treatment
(Figures 6I and 6J; Movies S1 and S2), suggesting the release
of VCAM-1-mediated cell-cell adhesion.
VCAM-1 Overexpression Is Dependent on NF-kB
Signaling
We tested several possible mechanisms for the activation of
VCAM-1 expression. We first ruled out gene copy number
change based on array CGH analysis at the VCAM-1 locus (Fig-
ure S1B) and quantitative PCR (data not shown). Next, we.
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Figure 6. VCAM-1-Mediated Attraction of Osteoclast Progenitors
(A) Chemotaxis of RAW264.7 to sVCAM-1 blocked by anti-VCAM-1 or anti-a4 antibodies.
(B) Chemotaxis of RAW264.7 to tumor-conditioned medium. In (A) and (B), data represent the mean ± SD. ***p < 0.001 (Student’s t test).
(C) Scanning EM showing adhesion of RAW264.7 to PD2D but not to SCP6 or VCAM-1-silenced PD2D.
(D) FACS of murine bone marrow showing a4+b1+ (P3) and a4b1+ (P2) cells in CD45+CD11b+ monocytes (P1). Sorted P3, but not P2, differentiated into TRAP+
osteoclasts under induction. Scale bar, 500 mm.
(E) FACS quantification of CD11b+ monocytes in CD45+ bone marrow leukocytes of mice injected with PD2D with or without bone metastases formed, as well as
of age-matched mice without injection (control).
(F) FACS quantification of a4+b1+ and a4b1+ subpopulations of CD11b+monocytes in bonemarrow ofmice injectedwith PD2Dwith or without bonemetastases
formed.
(G) FACS quantification of CD11b+ monocyte population in CD45+ peripheral blood leukocytes of mice injected with PD2D with or without bone metastases
formed, as well as of age-matched mice with established PD2D primary tumors. In (E), (F), and (G), the percentage was reported after excluding tumor cells
(positive for human HLA-ABC), if they exist. Data represent the mean ± SD. *p < 0.05, ***p < 0.001 (Student’s t test).
(H) Experimental flow of EviBoM. Green dots represent monocytes expressing the CX3CR1-EGFP knock-in gene.
(I) Representative EviBoM image frames and tracked movement of CX3CR1-EGFP
+ monocytes with IgG or anti-VCAM-1 ex vivo treatment. Scale bar, 30 mm.
(J) Comparison of median tracking velocity of CX3CR1-EGFP
+ monocytes in (I). Black bar represents the median of all data (Student’s t test). See also Figure S5,
Movies S1 and S2.
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VCAM-1 Activates Indolent Bone Metastasishypothesized that the signaling pathways essential for driving
VCAM-1 upregulation are constitutively active in VCAM-1+ PD
cells. Previous studies on VCAM-1 regulation identified multiple
regulatory pathways or factors, including NF-kB, p300/CBP,
protein kinase C, mitogen-activated protein kinase kinase
1/2, phospholipase C, mammalian target of rapamycin, phos-
phatidylinositol 3-kinase, epidermal growth factor receptor,
and miR-126 (Iademarco et al., 1992; Lee et al., 2008; MinamiCanand Aird, 2001). To identify the pathway that might be involved
in VCAM-1 upregulation, we used pharmacological inhibitors
to inactivate each of these pathways in PD1 and PD2D and
looked for consistent decrease of VCAM-1 expression (Fig-
ure S6A). Two pathways known to be important for bone metas-
tasis, Src (Zhang et al., 2009) and transforming growth factor
b (Kang et al., 2005), were also analyzed pharmacologically
(Figure S6B). Among these inhibitors that we tested, only twocer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc. 709
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Figure 7. VCAM-1 Upregulation Is Dependent on
NF-kB Activity
(A) Dose-dependent inhibition of VCAM-1 expression by
NF-kB pathway inhibitors MG132 and helenalin as de-
tected by western blot analysis.
(B) Inhibition of VCAM-1 expression by ectopic IkBaM
expression as detected by western blot analysis.
(C) Differential abundance of nuclear RelA and cyto-
plasmic IkBa in SCP6 and VCAM-1+ PD cells as detected
by western blot analysis.
(D) EMSA showing stronger band shift in PD1 and PD2D
compared with SCP6. Wild-type competitive probe (wt)
and inhibitors MG132 and helenalin, but not mutated
competitive probe (mut), blocked radioactive NF-kB-
specific probe binding. See also Figure S6.
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VCAM-1 Activates Indolent Bone Metastasisinhibitors of the NF-kB pathway, MG132 (Fiedler et al., 1998)
and helenalin (Lyss et al., 1998), blocked VCAM-1 expression
at 0.1-1 mM concentration (Figure 7A; Figure S6A). To further
confirm the role of NF-kB signaling in sustaining VCAM-1
expression, we genetically blocked the canonical NF-kB
signaling with enforced expression of IkBaM, a dominant-nega-
tive form of NF-kB inhibitor a (IkBa) (Brown et al., 1995). IkBaM
effectively reduced the VCAM-1 level (Figure 7B). Consistently,
PD cells contained less IkBa in the cytoplasm and more RelA
in the nucleus compared with SCP6 (Figure 7C). Direct evidence
of increased NF-kB activity in PD cells was shown by electro-
phoretic mobility shift assay (EMSA) (Figure 7D). To test whether
ectopic stimulation of NF-kB activity can drive VCAM-1 expres-
sion in SCP6, we treated SCP6 with tumor necrosis factor a,
which is a known activator of NF-kB signaling, and observed
a significant increase of VCAM-1 messenger RNA level, yet the
level was still dramatically lower than that in PD cells (Figures
S6C and S6D). This result suggests other mechanisms may
function cooperatively with NF-kB or independently to activate
VCAM-1 expression.
VCAM-1 Expression Associated with Clinical Early
Recurrence
To evaluate the clinical importance of VCAM-1 in breast cancer,
especially in the context of recurrence, we analyzed a breast
cancer microarray dataset containing metastasis relapse infor-
mation (Wang et al., 2005). The proportional relapse rate plot
showed the typical biphasic distribution of breast cancer
relapses with 30 months as the peak (Figure 8A) (Stearns et al.,
2007). When VCAM-1 levels were compared between early
and late recurrence groups using 30months as a cutoff to stratify
patients, higher VCAM-1 expression was significantly associ-
ated with early relapse (Figure 8B). To corroborate conclusion
from in silico analysis, we stained VCAM-1 in a breast cancer
tissue microarray (TMA) that contains 170 samples (Hu et al.,
2009). Higher VCAM-1 expression in cancerous tissue was again
correlated with early relapse (Figure 8C). These findings vali-
dated the clinical significance of VCAM-1 overexpression in early
relapse of breast cancer.710 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc.DISCUSSION
Significant progress has beenmade to elucidate
the molecular mechanisms of the multistepmetastasis cascade. However, the mechanism underlying meta-
static dormancy and relapse from the dormancy remains one of
most challenging but also clinically relevant questions (Aguirre-
Ghiso, 2007; Goss and Chambers, 2010). Our characterization
of a bone metastasis mouse model has shed light on the molec-
ular understanding of dormancy by showing that VCAM-1 is an
essential protein that reactivates indolent micrometastasis in
the bone microenvironment (Figure 8D).
A Metastasis Dormancy Animal Model
The most frequent sites of breast cancer metastasis include
bone, lung, liver, and brain. Metastasis relapse can occur in
any of these organs, and several attempts have been made to
model metastasis dormancy in these sites. Survival of tumor
cells during bone metastasis latency was linked to Src activity
(Zhang et al., 2009). Progression of lung micrometastasis to
macrometastasis in the transgenic MMTV-PyMT model was
shown to be triggered by angiogenesis (Gao et al., 2008). Solitary
tumor cells in the liver were visualized after intravenous injec-
tion of a murine mammary carcinoma cell line (Naumov et al.,
2002). However, these models did not investigate the sponta-
neous in vivo activation of indolent micrometastasis, which
represents the last phase of transition from dormancy to overt
metastasis.
Our serendipitous observation of rare macrometastatic
outgrowths after a long-term latency inmice allowed us to isolate
reactivated cancer cells and compare them with the indolent
parental cells to identify gene expression variations that may
have led to the escape from dormancy. The transition from
indolent growth to overt metastasis, as observed in our model,
occurs in patients with metastasis recurrence many years after
mastectomy. However, it is currently not feasible to prospec-
tively isolate a tumor cell predicted to escape dormancy from
a heterogeneous pool of disseminated tumor cells in patients.
In fact, even in basic research, studies on in vivo metastasis
dormancy are complicated by the heterogeneous growth prop-
erties of most cancer cell lines (Townson and Chambers,
2006): the behavior and characteristics of the minor dormant
subpopulations are masked by the coexisting actively
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Figure 8. VCAM-1 Expression Is Associated with Clinical Early Recurrence
(A) Bimodal pattern of metastasis relapse in a breast cancer cohort (Wang et al., 2005). Dotted line separates early and late relapse at 30 months, the peak of
the curve.
(B) VCAM-1 is expressed at a higher level in the early compared with the late metastasis relapse group. Data represent the mean ± SEM (Student’s t test).
(C) VCAM-1 expression correlates with early recurrence in a breast cancer TMA. Also shown are representative breast carcinoma TMA samples stained
for VCAM-1.
(D) A schematic model for the function of VCAM-1 in the transition from dormant micrometastasis to macrometastasis in bone. Incidental activation of VCAM-1,
a process possibly dependent on NF-kB signaling and other unidentified mechanisms (1), in micrometastasis arrests a4b1-positive osteoclast progenitors
through paracrine chemotaxis (2) and adhesion (3). This leads to a localized increase of the osteoclast progenitor population and increased mature osteoclast
activity (4). Activated osteoclasts resorb the bone and instigate the vicious cycle of bone metastasis (5).
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VCAM-1 Activates Indolent Bone Metastasisproliferating cells. These difficulties highlight the merit of our
model. Because of the relatively homogeneous nature of the
parental cell SCP6 (derived from a single clone) and the close
relatedness of SCP6 with PD sublines, the genome-wide
comparison of dormant and reactivated cells is particularly infor-
mative. Indeed, we identified VCAM-1 from this model as a key
player in metastatic progression from dormancy.
A Functional Role for VCAM-1 in Activating Indolent
Micrometastasis
Our mechanistic investigation of the function of VCAM-1 in
promoting the escape from dormancy revealed its connection
with osteoclastogenesis. By creating a ‘‘molecular sink’’ to
attract circulating monocytic precursors of osteoclasts through
VCAM-1-a4b1 interactions, VCAM-1 instigates a vicious cycle
of bone destruction and tumor expansion. As such, VCAM-1
serves as an example of how shifting the physiological process
of bone homeostasis can facilitate the expansion of nascent
bone metastasis. However, we should mention that, in contrast
to other previously identified bone metastasis factors such as
Jagged1 (Sethi et al., 2011), VCAM-1 is not sufficient for osteo-
clast differentiation, as neither RAW264.7 cells nor murine
bone marrow cocultured with VCAM-1+ PD cells or plated on
a VCAM-1-coated surface underwent differentiation without
RANKL (data not shown). In addition, although it appears that,
in this particular model system, VCAM-1 is likely to be a key
factor for the recruitment of preosteoclasts to nascent boneCanmicrometastasis, we do not rule out other chemoattractants
playing contributing roles to this process. It is possible that
such factors were upregulated in PD cells posttranscriptionally
or posttranslationally, which could not be captured by our micro-
array analysis. We also want to point out a possible and unex-
plored regulatory checkpoint of VCAM-1 availability in our
system, which is the proteolysis and shedding of sVCAM-1
from tumor cell membranes through the activity of metalloprotei-
nases (Garton et al., 2003).
It is well established that a4b1 is important in bone marrow
homing and retention of hematopoietic stem cells through its
binding to VCAM-1 expressed in bone marrow endothelial and
stromal cells (Papayannopoulou et al., 2001). It is reasonable
to speculate that the interaction between VCAM-1 and a4b1 is
also part of the program regulating monocyte retention in bone
marrow. In support of this hypothesis, VCAM-1-deficient mice
showed elevated blood mononuclear leukocytes, possibly due
in part to the reduced retention of these cells in the bone marrow
(Gurtner et al., 1995). Therefore, it is conceivable that breast
cancer cells, by upregulating VCAM-1, could imitate the marrow
endothelial and stromal cells to locally retain high density of
monocytes as the source of osteoclast differentiation.
We noted that even with the inhibition of VCAM-1, PD2D cells
could still expand more than 10-fold to form a micrometastasis
with probably a few hundreds cells (Figures 4A and 5A). Our
evidence suggests that VCAM-1 is crucial for the expansion of
indolent bonemicrometastasis but is dispensable for the survivalcer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Inc. 711
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VCAM-1 Activates Indolent Bone Metastasisand initial growth of solitary tumor cells, the immediate step of
metastatic colonization after seeding.On the other hand, a recent
report showed that binding of VCAM-1-overexpressing tumor
cells to macrophages directly promotes signal flow through the
PI3K-Akt pathway for the survival of breast cancer cells that
infiltrate the lung, but is not required for the immediate survival
of those that seed the bone marrow (Chen et al., 2011). Never-
theless, in tissue samples of overt metastasis lesions from breast
cancer patients, VCAM-1was found to be overexpressed in both
lung and bone metastases (Chen et al., 2011). Taken together,
these findings indicate that VCAM-1 plays important functions
in promoting metastatic colonization in both bone and lung,
although at different stages and through different mechanisms.
Therefore, blocking VCAM-1 activity may represent an effective
strategy to prevent the formation of overt metastasis in both
bone and lung, two of the most frequent sites of distant relapse
in breast cancer.
Inflammation, NF-kB Signaling, and VCAM-1 Regulation
Inflammation has long been hypothesized to be linked to cancer
based on the pathological infiltration of leukocytes in neoplastic
tissue as well as the association of chronic inflammation
and infectious agents with cancer (Grivennikov et al., 2010).
An inflammatory microenvironment, triggered by an infection,
trauma, or stress, has been proposed to waken dormant tumor
cells (Fehm et al., 2008), although experimental evidence is
lacking. The canonical NF-kB pathway plays a central role in
mediating the effect of inflammation on tumor progression
(Grivennikov et al., 2010). Here, we found that VCAM-1 expres-
sion in PD cells is dependent on constitutive NF-kB activity.
Therefore, our study suggests a possible link between the
NF-kB pathway and recurrent bone metastasis, although direct
evidence showing the causal role of N-FkB activation in the
metastatic progression from dormancy is lacking and warrants
further experimental validation. Supporting the functional sig-
nificance of the NF-kB pathway in bone metastasis, NF-kB
has been shown to stimulate granulocyte M-CSF expression
in tumor cells to promote osteoclastogenesis and bone metas-
tasis (Park et al., 2007). Other factors regulated by NF-kB
may also contribute to metastasis progression, such as
CXCL1 and CSF-1 which are also expressed by PD cells,
although not at a significantly higher level when compared
with SCP6 (data not shown). The other two well-known NF-kB
targets, CCL2 and CCL5, are expressed at negligible levels in
PD cells.
Single-Cell Imaging of Tumor-Stromal Interactions
in Bone Metastasis
A significant technical contribution of our study is the develop-
ment of EviBoM (Figure 6H) imaging technique for bone metas-
tasis research. Optical intravital imaging has attracted increasing
interest in the field of metastasis research, because it offers high
spatial and temporal resolution in vivo and enables direct obser-
vation of metastasis at the single cell resolution (Sahai, 2007).
Intravital imaging has lent strength to tumor dormancy research
in studies characterizing tumor cell fates at secondary organs
(Kienast et al., 2010; Naumov et al., 2002). Mouse skull was
previously used as the site to study leukemia bone metastasis
with in vivo confocal imaging (Sipkins et al., 2005). However,712 Cancer Cell 20, 701–714, December 13, 2011 ª2011 Elsevier Incmetastases in long bones (in particular, femur and tibia of the
legs) are much more commonly associated with clinical and
experimental bone metastasis. We developed EviBoM to
provide real-time observation of cell movement in long bone
metastases, although it is still in an ex vivo setting. A limitation
of the current method is that osteoclast progenitors only repre-
sent a fraction of the GFP+ cells in the CX3CR1-EGFP mice.
More lineage-specific labeling will improve the application of Evi-
BoM and facilitate mechanistic investigation and preclinical drug
development for bone metastasis.
EXPERIMENTAL PROCEDURES
Tumor Xenografts and Analysis
All procedures involving mice were approved by the Institutional Animal Care
andUse Committee of PrincetonUniversity. Intracardiac injections to generate
bone metastases was performed in 4-week-old, female nude mice (National
Cancer Institute) as described (Lu and Kang, 2009), with the exception of
TM40D-BM, which was injected into BALB/c mice (National Cancer Institute).
Development of metastasis in bone was monitored by BLI with the IVIS 200
Imaging System (Caliper Life Sciences) and analyzed with the Living Image
software as described (Lu and Kang, 2009). X-ray examination was performed
as described (Kang et al., 2003).
Clinical Specimens
A breast cancer TMA composed of 170 primary tumors (Hu et al., 2009) was
used in our association study. Breast tumor specimens used in the TMA
were obtained from the Cancer Institute of New Jersey with informed consent
from all subjects in accordance with the institutional review boards of Prince-
ton University and the University of Medicine and Dentistry of New Jersey, and
the samples were subsequently deidentified prior to analysis. More detailed
information about immunohistochemical analysis of VCAM1-1 expression in
TMA can be found in the Supplemental Information.
EviBoM
We stably labeled PD2D with retroviral vectors expressing firefly luciferase
(cloned into pMSCVhygro) and mKeima (cloned into pMSCVpuro), and
intracardiacally injected tumor cells into CX3CR1-EGFP knock-in mice (The
Jackson Laboratory) that had been crossed to harbor homozygous nu
alleles. After detection of significant bone metastasis formation by BLI, we
located the position of bone metastasis via ex vivo BLI, sectioned the bone
with QwikStrip Serrated strip (Axis Dental), and embedded them into a thin
layer of 1.5% lowmelting temperature agarose gel that is submerged in phenol
red-free Dulbecco’s modified Eagle’s medium (Thermo Scientific) containing
13 penicillin-streptomycin and 10 mM HEPES (balancing pH). The bone
sections were imaged under a customized upright multiphoton microscope
built around a BX51 microscope (Olympus). More detailed methods can be
found in the Supplemental Information.
Statistical Analysis
Results were reported as mean ± SD or mean ± SEM, indicated in the figure
legend. Comparisons between Kaplan-Meier curves were performed using
the log-rank test. Other comparisons were performed using unpaired two-
sided Student’s t test without equal variance assumption or nonparametric
Mann-Whitney test.
ACCESSION NUMBERS
The raw and normalized microarray data have been deposited in the Gene
Expression Ominbus database under accession number GSE20611.
SUPPLEMENTAL INFORMATION
Supplemental information includes six figures, one table, two movies, and
Supplemental Experimental Procedures and can be found with this article
online at doi:10.1016/j.ccr.2011.11.002..
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